Global repression of mesenchymal genes in epithelial cells by the histone demethylase LSD1
This study demonstrates that in epithelial cells, LSD1 functions to maintain epithelial identity by constitutively repressing mesenchymal genes, thereby challenging the therapeutic strategy of using LSD1 inhibition to control epithelial-mesenchymal transition.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cells in the human body generally fall into two broad categories based on how they behave and where they live. Some cells, known as epithelial cells, stick together tightly to form protective sheets, like the skin or the lining of the gut. They are stationary and focused on maintaining a barrier. Others, called mesenchymal cells, are more like wanderers; they are loose, mobile, and capable of moving through tissues to repair damage or, in the case of cancer, to spread to new locations. A critical biological process called the epithelial-to-mesenchymal transition allows a stationary cell to shed its tight bonds, change its shape, and become a mobile wanderer. This transformation is essential for healing wounds and for embryonic development, but when it goes wrong in adults, it can drive cancer to spread throughout the body. For years, scientists have believed that a specific protein called LSD1 acts as a villain in this story, helping cancer cells become mobile and invasive. This belief led to the development of drugs designed to block LSD1, with the hope of stopping cancer from spreading.
However, a new study published by researchers at the University of Leicester and the University of Birmingham suggests that the role of LSD1 is far more complicated than previously thought. By watching what happens inside living cells when this protein is suddenly removed, the team discovered that LSD1 actually acts as a guardian of the stationary state in healthy-looking cells. When the researchers removed LSD1 from epithelial cells, the cells did not stay put; instead, they began to change, activating the very genes that turn them into mobile, invasive wanderers. This finding challenges the idea that simply blocking LSD1 will always stop cancer, suggesting that in some contexts, the drug might accidentally encourage the very behavior it is meant to prevent.
To investigate this, the researchers worked with a specific type of human colon cancer cell that naturally behaves like a stationary epithelial cell. They engineered these cells so that they could remove the LSD1 protein almost instantly, like flipping a switch, rather than slowly degrading it over days. This allowed them to watch the immediate reaction of the cell's genetic machinery. Within just one hour of removing the protein, the cells began to change their behavior. The researchers measured the activity of thousands of genes and found that removing LSD1 caused a massive surge in the activity of genes associated with movement and invasion. These were not random changes; the cells were turning on a specific program that tells them to leave their stationary position and become mobile.
The team looked closely at the DNA to understand how this happened. They found that in normal, stationary cells, the LSD1 protein is already sitting on the DNA of these movement-related genes, acting like a brake. It keeps these genes turned off, ensuring the cell stays put. When the researchers removed LSD1, they took their foot off the brake. The genes for movement immediately started firing, and the cells began to produce proteins that help them move. Crucially, the researchers observed that the DNA in these areas was already open and ready to be read; the LSD1 protein was the only thing stopping the cell from using that information. Once the protein was gone, the cell's internal machinery rushed to read those instructions, leading to a rapid shift in the cell's identity.
The study also tracked what happened to the physical structure of the cells. After removing LSD1, the cells lost their tight connections to one another and became more rounded and mobile, a clear sign that they were undergoing the transition to a wandering state. They moved faster across a surface in a test tube, mimicking the behavior of invasive cancer cells. The researchers then tested whether this change was permanent or if the cells could return to normal if the LSD1 protein was put back. When they restored the protein, the cells did not fully return to their original state. While some of the movement genes were turned down, the genes that keep cells stuck together were not just turned off, but were further repressed. This suggests that once the cell starts to change, it may not easily go back, even if the initial trigger is removed.
A significant part of the research involved comparing this rapid removal of the protein with the use of chemical drugs that block LSD1's activity. Scientists had hoped that these drugs would mimic the effect of removing the protein, but the results were surprisingly different. The chemical drugs affected a much wider range of genes and did not produce the same clear, specific pattern of change seen when the protein was physically removed. This indicates that the drugs might be interfering with other processes in the cell or that the protein has a role in the cell that goes beyond just its enzymatic activity. The difference between removing the protein and blocking its activity suggests that current drug trials might not be capturing the full picture of how LSD1 works in the body.
The implications of these findings are significant for how scientists think about treating cancer. For years, the strategy has been to inhibit LSD1 to stop cancer cells from spreading. This new work suggests that in cells that are still mostly stationary, blocking LSD1 might actually push them toward becoming mobile, potentially making the cancer more dangerous rather than less. The researchers propose that LSD1 acts as a global regulator that keeps the wrong genes turned off, whether the cell is supposed to be stationary or mobile. In stationary cells, it keeps movement genes off; in mobile cells, it likely keeps stationary genes off. Removing this regulator in either state can lead to confusion and a loss of identity.
This study does not claim that LSD1 inhibitors are useless, but it does suggest that their effects depend heavily on the type of cell they are targeting. In cells that are already mobile, blocking LSD1 might still help stop them from spreading. But in cells that are still stationary, the same treatment could have the opposite effect, priming them to become invasive. The researchers emphasize that understanding these subtle differences is essential before moving forward with treatments. The complexity of the cell's response means that a simple "one-size-fits-all" approach to targeting this protein may not work. Instead, doctors and scientists may need to look more closely at the specific state of a patient's cancer cells to determine if blocking LSD1 will help or harm. The study serves as a reminder that biological systems are often more nuanced than our initial models suggest, and that the tools we use to fight disease must be precise enough to account for these hidden layers of control.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.